Приказ основних података о документу
Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab
dc.creator | Beyer, GJ | |
dc.creator | Miederer, M | |
dc.creator | Vranješ-Đurić, Sanja | |
dc.creator | Čomor, Jožef J. | |
dc.creator | Kunzi, G | |
dc.creator | Hartley, O | |
dc.creator | Senekowitsch-Schmidtke, R | |
dc.creator | Soloviev, D | |
dc.creator | Buchegger, F | |
dc.date.accessioned | 2018-03-01T19:26:58Z | |
dc.date.available | 2018-03-01T19:26:58Z | |
dc.date.issued | 2004 | |
dc.identifier.issn | 1619-7070 | |
dc.identifier.uri | https://vinar.vin.bg.ac.rs/handle/123456789/2757 | |
dc.description.abstract | This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide. Radio-immunotherapy with 5.5 MBq labelled antibody conjugate (1.11 GBq/mg) 2 days after an intravenous graft of 5.10(6) Daudi cells resulted in tumour-free survival for GT 120 days in 89% of treated animals. In contrast, all control mice (no treatment or treated with 5 or 300 mug unlabelled rituximab) developed lymphoma disease. At the end of the study period, 28.4%+/-4% of the long-lived daughter activity remained in the body, of which 91.1% was located in bone tissue and 6.3% in the liver. A relatively high daughter radioactivity concentration was found in the spleen (12%+/-2%/g), suggesting that the killed cancer cells are mainly eliminated through the spleen. This promising preliminary in vivo study suggests that targeted alpha therapy with Tb-149 is worthy of consideration as a new-generation radio-immunotherapeutic approach. | en |
dc.rights | restrictedAccess | en |
dc.source | European Journal of Nuclear Medicine and Molecular Imaging | en |
dc.subject | alpha particle-emitting radionuclides | en |
dc.subject | terbium-149 | en |
dc.subject | radio-immunotherapy | en |
dc.subject | rituximab | en |
dc.subject | leukaemia | en |
dc.title | Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab | en |
dc.type | article | en |
dcterms.abstract | Буцхеггер, Ф; Беyер, ГЈ; Миедерер, М; Врањес-дуриц, С; Цомор, ЈЈ; Кунзи, Г; Хартлеy, О; Сенекоwитсцх-Сцхмидтке, Р; Соловиев, Д; | |
dc.citation.volume | 31 | |
dc.citation.issue | 4 | |
dc.citation.spage | 547 | |
dc.citation.epage | 554 | |
dc.identifier.wos | 000220298600013 | |
dc.identifier.doi | 10.1007/s00259-003-1413-9 | |
dc.citation.rank | M21a | |
dc.identifier.pmid | 14722680 | |
dc.identifier.scopus | 2-s2.0-1842714861 |
Документи
Датотеке | Величина | Формат | Преглед |
---|---|---|---|
Уз овај запис нема датотека. |